Article Figures & Data
Figures
- FIGURE 1.
Prostate biopsy algorithm for study subjects. DRE = digital rectal examination.
- FIGURE 2.
Receiver-operating-characteristic curve analysis of 68Ga-PSMA PET/CT semiquantitative analysis index for prediction of csPCa. SUVT/BGp = tumor–to–normal-prostate background SUVmax.
Tables
Characteristic Non-csPCa csPCa P Patients (n) 19 12 Age (y) 63 (53–81) 70.5 (57–81) 0.152 Prior biopsies (n) 1 (1–3) 1 (1–3) 0.857 Total PSA (ng/mL) 10.63 (5.48–46.88) 37.58 (8.96–49.77) 0.002* Free/total PSA (ng/mL) 0.15 (0.07–0.47) 0.13 (0.02–0.74) 0.562 Prostate volume (cm3) 56.22 (22.39–108.63) 33.69 (7.79–74.36) 0.023* PSA density (ng/mL/mL) 0.16 (0.09–1.75) 0.81 (0.29–2.31) <0.001* ↵* Significant differences (P < 0.05).
csPCa has GS ≥ 7; non-csPCa has GS of 6 or is normal prostate or benign prostatic disease. Data are median followed by range in parentheses. P values are for Wilcoxon–Mann–Whitney U test.
- TABLE 2
Comparison of Semiquantitative Analysis Parameters of 68Ga-PSMA PET/CT Between csPCa and Non-csPCa
Parameter Non-csPCa csPCa P SUVmax of prostate lesion 4.63 (2.90–9.87) 10.15 (5.45–30.95) <0.001* SUVmax for… Liver background 5.47 (3.05–9.74) 5.42 (4.62–8.60) 0.484 Prostate background 3.3 (2.00–4.40) 3.5 (2.70–4.20) 0.130 Prostate lesions vs. prostate background 1.43 (1.12–4.94) 3.36 (1.44–10.32) <0.001* Prostate lesions vs. liver background 0.91 (0.64–2.12) 1.48 (1.03–6.03) <0.001* ↵* Significant differences (P < 0.05).
csPCa has GS ≥ 7; non-csPCa has GS of 6 or is normal prostate or benign prostatic disease. Data are median followed by range in parentheses. P values are for Wilcoxon–Mann–Whitney U test.
Supplemental Data
Files in this Data Supplement:
